CROI 2016 Program at a Glance

Program and Agenda

S. Maternal/Fetal HIV P-S1 HIV Acquisition and Health Outcomes During Pregnancy (Tuesday, February 23, 2016) P-S2 AntiretroviralTherapy Pharmacokinetics and Safety During Pregnancy and Infancy (Tuesday, February 23, 2016) P-S3 Partners in Crime: CMV, HIV, and MTCT (Tuesday, February 23, 2016) P-S4 MTCT: Regimens, Rates, and Early Infant Diagnosis (Tuesday, February 23, 2016) P-S5 Mind the Gaps: Optimizing the PMTCT Cascade (Wednesday, February 24, 2016) P-S6 Viral Dynamics and Drug Resistance During Pregnancy (Wednesday, February 24, 2016) P-S7 Birth Outcomes and Mortality in HIV- and ARV-Exposed Infants (Wednesday, February 24, 2016) P-S8 Viral and Immune Mechanisms of MTCT (Thursday, February 25, 2016) P-S9 Outcomes of HIV and ARV-Exposed Infants, Children, andYouth (Thursday, February 25, 2016) T. Pediatrics and Adolescents P-T1 Pharmacokinetics: Efficacy and Safety of New ARVs in Children (Tuesday, February 23, 2016) P-T2 Getting a Handle on CNS Disease in Children and Adolescents (Tuesday, February 23, 2016) P-T3 Immunopathogenesis in HIV-Infected Children (Tuesday, February 23, 2016) P-T4 Test,Treat, and Suppress: Achieving 90-90-90 in Adolescents (Wednesday, February 24, 2016) P-T5 AntiretroviralTherapy andViral Suppression in Children: Implications for Cure (Wednesday, February 24, 2016) P-T6 Achieving 90-90-90 in Children (Thursday, February 25, 2016) P-T7 HIV Drug Resistance in Children (Thursday, February 25, 2016) P-T8 Complications of HIV and AntiretroviralTherapy in Children (Thursday, February 25, 2016) P-T9 Cotreatments of Coinfections in Children (Thursday, February 25, 2016) U. Contraception and Reproductive and Sexual Health in Women P-U1 Contraception and Sexual Health inWomen (Thursday, February 25, 2016) V. Prevention and Intervention Studies P-V1 It’s Complicated: Renal Function and STIs in PrEP Users (Tuesday, February 23, 2016) P-V2 Topical and Systemic Preexposure Prophylaxis: New Agents, New Populations (Wednesday, February 24, 2016) P-V3 Predictors of PrEP Coverage and Uptake (Thursday, February 25, 2016) P-V4 PrEP in Primary Care: Pitfalls and Opportunities (Thursday, February 25, 2016)

W. Epidemiology P-W1 Populations at Risk for HIV (Tuesday, February 23, 2016) P-W2 Infection Status, Care, and Mortality (Tuesday, February 23, 2016) P-W3 Sex, Drugs, Depression, and HIV (Tuesday, February 23, 2016) P-W4 MSM in Low- and Middle-Income Countries (Wednesday, February 24, 2016) P-W5 Individuals at Risk of HIV (Thursday, February 25, 2016) X. Implementation Science and Health Care Delivery P-X1 Insights from AntiretroviralTherapy Use: High-Income Settings (Tuesday, February 23, 2016) P-X2 Insights from AntiretroviralTherapy Use: Low-Income Settings (Tuesday, February 23, 2016) P-X3 HIVTesting and Prevention (Wednesday, February 24, 2016) P-X4 HIV Care in the Global North (Wednesday, February 24, 2016) P-X5 HIV Care, Financing (Wednesday, February 24, 2016) P-X6 HIV and Other SexuallyTransmitted Infections (Thursday, February 25, 2016) P-X7 Access, ART Initiation, Retention, and Outcomes in the Global South (Thursday, February 25, 2016) P-X8 Viral Suppression (Thursday, February 25, 2016) Y. Population and Economic Modeling P-Y1 Modeling: Understanding Epidemics and ART Programs (Tuesday, February 23, 2016) P-Y2 Going to ScaleWith ART and PrEP (Wednesday, February 24, 2016) P-Y3 Modeling the (Cost) Efficiency ofTesting and Prevention (Wednesday, February 24, 2016)

Poster Sessions

52

CROI 2016